TABLE 3.
Targeted agent feasibility & safety profile
| NMTRC012 pilot | N = 20 |
|---|---|
| Targeted agent feasibility & safety profile | |
| Tumor board recommended agent, # subjects (%) | |
| Vorinostat (230 mg/m2/dose oral daily) | 16 (80%) |
| Crizotinib (165 mg/m2/dose oral twice daily) | 2 (10%) |
| Dasatinib (60 mg/m2/dose oral daily) | 1 (5%) |
| Sorafenib (150 mg/m2/dose oral twice daily) | 1 (5%) |
| Start of targeted agent, # subjects (%) | |
| Cycle 3, Day 1 | 15 (75%) |
| Cycle 3, after Day 1 | 4 (20%) |
| Cycle 5, Day 1 | 1 (5%) |
| Toxicity‐associated events, # subjects (%) | |
| Targeted agent holds | 8 (40%) |
| Targeted agent dose reductions | 2 (10%) |
| Targeted agent discontinuation | 0 (0%) |
| Cycle delays (>7 days) | 7 (35%) |
| Completed cycles of induction, # subjects (%) | |
| Six cycles | 19 (95%) |
| Five cycles | 1 (5%) |
| Feasibility of targeted agent | |
| Completed ≥75% | 17 (85%) |
| Completed <75% | 3 (15%) |